Komori
KYORIN Pharmaceutical (4569) · TargetReframed

Achieving a Growth Trend through the Pursuit of Originality

First written in FY2020. 4 of 6 entries say "Restated". Latest entry: FY2023.

6entries
4years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2020 – FY2023-Q12020: 320202021: 120212022: 120222023: 12023
Same theme, other companies
Achieving growth trends through unique competitive strengthsA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2023ReframedAnnual report

    「Our aspiration is to be a company that places its new pharmaceutical business, which continuously provides high-value new drugs that meet medical needs, at the core of its operations, develops a broad range of health-related businesses, and contributes extensively to people's health. We will work to make this aspiration a reality.」

    The expression was revised from Stage 3's “Achieving a growth trend by pursuing originality” to the Vision 110 aspiration of making the new pharmaceutical business the core and developing a broad range of health-related businesses.
  2. FY2023-Q1RestatedAnnual report

    「The management policy for the fiscal year ending March 2023 adopted “Achieving a growth trend by pursuing originality,” with improving business “speed” as a key focus of the business strategy,」

    The Stage 3 statement, “Achieving a growth trend by pursuing originality,” continues as the management policy for the fiscal year ending March 2023.
  3. FY2021-Q3RestatedAnnual report

    「The management policy for the fiscal year ending March 2021 adopted “Pursuing challenges to achieve originality.” Under its business strategy, the Group is working to accelerate the growth of its new drug portfolio, expand its development pipeline and drug discovery projects, and enhance cost competitiveness, with the aim of firmly shifting to a growth trend.」

    The business strategy based on “Achieving a growth trend by pursuing originality” continues.
  4. FY2021-Q2RestatedAnnual report

    「The Group adopted “Achieving a growth trend by pursuing originality” as its statement and is promoting business and organisational strategies to achieve its performance targets and enhance the support and recognition it receives from stakeholders.」

    The Stage 3 statement and the related business and organisational strategies continue.
  5. FY2021-Q1RestatedAnnual report

    「The Group adopted “Achieving a growth trend by pursuing originality” as its statement and promoted business and organisational strategies,」

    The Stage 3 statement, “Achieving a growth trend by pursuing originality,” and the related business and organisational strategies continue.
  6. FY2020First statedAnnual report

    「The new medium-term management plan, “HOPE100 – Stage 3 –,” adopts “Achieving a growth trend through the pursuit of originality” as its statement.」

    Stage 3 newly adopted a policy of pursuing distinctive competitive initiatives beyond conventional thinking and methods to achieve a growth trend.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for KYORIN Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.